5 trends tracked about this subject — the full history, oldest to newest below.
Novartis's pelacarsen fails to reduce cardiovascular events in the Lp(a)HORIZON trial, casting doubt on lipoprotein(a) as a drug target and AI-driven drug discovery.
A major Cleveland Clinic-led trial reveals that a targeted drug successfully lowered lipoprotein(a) without reducing major heart events.
Recent reporting highlights lipoprotein(a) as a hidden genetic stroke and heart disease risk factor affecting one in five people.
Lipoprotein(a) moves from lab curiosity to market‑ready target as new drugs and testing surge forward
Recent health reports highlight Lipoprotein(a) as a hidden genetic heart risk that can threaten cardiovascular health even when standard cholesterol levels appear normal.